AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17507365 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (remained in sinus rhythm)
Number of subjects: 47
Study 17507365 — intervention group
Group type: COMPARATOR
Intervention: Group II (recurrence of AF)
Number of subjects: 47
Study 17507365 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 47
Study 17507365 — intervention group
Group type: EXPERIMENTAL
Intervention: APC/h and max HR
Number of subjects: 47
Study 17507365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both predictors (APC/h and max HR)
Number of subjects: 47
Study 16327033 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CP) group
Number of subjects: 0
Study 16327033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 0
Study 16327033 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF) group
Number of subjects: 0
Study 12189364 — intervention group
Group type: COMPARATOR
Intervention: 30 mg ketorolac tromethamine (intravenous)
Number of subjects: 0
Study 12189364 — intervention group
Group type: COMPARATOR
Intervention: 1 mg ketorolac tromethamine (intramuscular or submucosal)
Number of subjects: 0
Study 12189364 — intervention group
Group type: COMPARATOR
Intervention: 1 mg ketorolac tromethamine (at the surgical site)
Number of subjects: 0
Study 12189364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10457293 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbent liners in cloth postural support nappies
Number of subjects: 23
Study 10457293 — intervention group
Group type: COMPARATOR
Intervention: No absorbent liners in cloth postural support nappies
Number of subjects: 23
Study 7475657 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3371
Study 7475657 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 3371
Study 2197908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, 400 mg/d for 10 weeks
Number of subjects: 21
Study 2197908 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B plus flucytosine
Number of subjects: 21
Study 2197908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 21
Study 282084 — intervention group
Group type: EXPERIMENTAL
Intervention: Three distinct antihypertensive drugs, administered alone and combined two‐by‐two.
Number of subjects: 10294
Study 282084 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10294
Study 31791209 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: voltage, 100 kVp, iodixanol, 270 mgI/mL
Number of subjects: 216
Study 31791209 — intervention group
Group type: COMPARATOR
Intervention: Group A: voltage, 120 kVp; iohexol, 350 mgI/mL
Number of subjects: 216
Study 31791209 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216
Study 31773310 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific positioning of the EVD in the setting of intracerebral hemorrhage with intraventricular hemorrhage
Number of subjects: 0
Study 31773310 — intervention group
Group type: COMPARATOR
Intervention: EVD management approaches
Number of subjects: 0
Study 31773310 — intervention group
Group type: EXPERIMENTAL
Intervention: EVDs
Number of subjects: 0
Study 27846418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 462
Study 25973914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii spores administered as lyophilized or liquid formulation
Number of subjects: 0
Study 25973914 — intervention group
Group type: COMPARATOR
Intervention: Bacillus clausii spores (liquid suspension)
Number of subjects: 0
Study 25973914 — intervention group
Group type: COMPARATOR
Intervention: Bacillus clausii spores (lyophilized form)
Number of subjects: 0
Study 23332366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB) 5 mg/d, titrated to 20 mg/d
Number of subjects: 432
Study 23332366 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 432
Study 23332366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB)
Number of subjects: 432
Study 21277745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg once daily
Number of subjects: 301
Study 21277745 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80 mg BID
Number of subjects: 301
Study 19498438 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine (40 mg day(-1))
Number of subjects: 60
Study 19498438 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg day(-1))
Number of subjects: 60
Study 16979844 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 30 Gy (dose/fraction 1.5 Gy, 16 patients)
Number of subjects: 191
Study 16979844 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 25.5 Gy (dose/fraction 1.5 Gy, 62 patients)
Number of subjects: 191
Study 16979844 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 20 Gy (dose/fraction 2 Gy, 69 patients)
Number of subjects: 191
Study 16979844 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose 26 Gy (dose/fraction 2 Gy, 29 patients)
Number of subjects: 191
Study 15003662 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclaved‐killed, whole cell Leishmania amazonensis vaccine plus BCG adjuvant
Number of subjects: 1506
Study 15003662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1506
Study 17201277 — intervention group
Group type: EXPERIMENTAL
Intervention: mexicor
Number of subjects: 101
Study 10224738 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 0
Study 10224738 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 0
Study 10224738 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8550957 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' diagnosis of depression
Number of subjects: 682
Study 8550957 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms described by GPs
Number of subjects: 682
Study 1775603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor HP 029 (doses not specified)
Number of subjects: 23
Study 1775603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7029742 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (Dolobid; Frosst‐MSD)
Number of subjects: 0
Study 7029742 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (Naprosyn; Syntex)
Number of subjects: 0
Study 31550817 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Number of subjects: 0
Study 31550817 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 29351310 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group intervention of seven weekly sessions of 120 min with a booster session after six weeks
Number of subjects: 115
Study 29351310 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 115
Study 29351310 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group intervention
Number of subjects: 115
Study 26710008 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglandular breast augmentation
Number of subjects: 58
Study 26710008 — intervention group
Group type: EXPERIMENTAL
Intervention: Submuscular breast augmentation
Number of subjects: 58
Study 26710008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 23420196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive resource depletion condition
Number of subjects: 81
Study 23420196 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 81
Study 22159880 — intervention group
Group type: COMPARATOR
Intervention: Group B (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000)
Number of subjects: 80
Study 22159880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BM (1.0 mL/kg of bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg)
Number of subjects: 80
Study 22159880 — intervention group
Group type: COMPARATOR
Intervention: Group BC (bupivacaine 0.166% with epinephrine 1:600,000 plus clonidine 1.0 μg/kg)
Number of subjects: 80
Study 22159880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BMC (bupivacaine 0.166% with epinephrine 1:600,000 plus morphine 20 μg/kg and clonidine 1.0 μg/kg)
Number of subjects: 80
Study 19889003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy alone
Number of subjects: 25
Study 19889003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy with added pioglitazone (45 mg)
Number of subjects: 25
Study 19889003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 17337398 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mug/day selenium for 3 years
Number of subjects: 184
Study 17337398 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 3 years
Number of subjects: 184
Study 15762971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (1 g intravenously before surgery)
Number of subjects: 548
Study 15762971 — intervention group
Group type: COMPARATOR
Intervention: 1-day cefazolin (1 g intravenously before surgery and three more doses every 6 hr after surgery)
Number of subjects: 548
Study 11879210 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ephedrine combination
Number of subjects: 100
Study 11879210 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 100
Study 10220835 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients
Number of subjects: 84
Study 10220835 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients with pulmonary hypertension
Number of subjects: 84
Study 7604787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin at 40 mg/day
Number of subjects: 21
Study 7604787 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil at 600 mg twice daily
Number of subjects: 21
Study 7604787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin and gemfibrozil
Number of subjects: 21
Study 7604787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 2196555 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine plus 1 g of paracetamol t.i.d.
Number of subjects: 19
Study 2196555 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol t.i.d.
Number of subjects: 19
Study 31888947 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative outpatient review 3 weeks after hospital discharge, followed by commencement of cardiac rehabilitation (CR) from 4 weeks
Number of subjects: 100
Study 31888947 — intervention group
Group type: COMPARATOR
Intervention: Postoperative outpatient review 6 weeks after hospital discharge, followed by CR commencement from 8 weeks
Number of subjects: 100
Study 29954449 — intervention group
Group type: EXPERIMENTAL
Intervention: FFIT Follow Up Intervention group (FFIT-FU-I)
Number of subjects: 665
Study 29954449 — intervention group
Group type: COMPARATOR
Intervention: FFIT Follow Up Comparison group (FFIT-FU-C)
Number of subjects: 665
Study 29954449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 665
Study 29954449 — intervention group
Group type: EXPERIMENTAL
Intervention: FFIT
Number of subjects: 665
Study 27093610 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK457 (40 g/day)
Number of subjects: 0
Study 27093610 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK457
Number of subjects: 0
Study 27093610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25142742 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (CV) to restore sinus rhythm (SR)
Number of subjects: 164
Study 22142170 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Action program (intervention)
Number of subjects: 20
Study 20919759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent substance involvement
Number of subjects: 80
Study 20919759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-reported PTS symptoms
Number of subjects: 80
Study 20919759 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported adolescent PTS symptoms
Number of subjects: 80
Study 17450046 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1.08 mg/day)
Number of subjects: 25
Study 17450046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15050486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban plus heparin
Number of subjects: 231
Study 15050486 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 231
Study 12512791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study 12512791 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study 9690573 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol powder (50 microg twice daily)
Number of subjects: 207
Study 9690573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 8579657 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler study of the systolic to diastolic ratio of the umbilical artery
Number of subjects: 92
Study 2569550 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fetal movement counting
Number of subjects: 68000
Study 2569550 — intervention group
Group type: COMPARATOR
Intervention: Standard care (selective use of formal counting or informal noting of movements)
Number of subjects: 68000
Study 560824 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr-Edwards aortic valve replacement (SE-AVR)
Number of subjects: 1518
Study 560824 — intervention group
Group type: COMPARATOR
Intervention: Hancock aortic valve replacement (X-AVR)
Number of subjects: 1518
Study 560824 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr-Edwards mitral valve replacement (SE-MVR)
Number of subjects: 1518
Study 560824 — intervention group
Group type: COMPARATOR
Intervention: Hancock mitral valve replacement (X-MVR)
Number of subjects: 1518
Study 560824 — intervention group
Group type: EXPERIMENTAL
Intervention: Starr-Edwards double-valve replacement (SE-AVR-MVR)
Number of subjects: 1518
Study 560824 — intervention group
Group type: COMPARATOR
Intervention: Hancock double-valve replacement (X-AVR-MVR)
Number of subjects: 1518
Study 31778140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ens-Grad machine learning method for designing complementarity determining regions of human Immunoglobulin G antibodies
Number of subjects: 0
Study 31778140 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning approach
Number of subjects: 0
Study 31503048 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 60
Study 31503048 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 60
Study 31503048 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine
Number of subjects: 60
Study 27631964 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral health home
Number of subjects: 447
Study 27631964 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 447
Study 26233289 — intervention group
Group type: EXPERIMENTAL
Intervention: N-palmitoylethanolamine (PEA) and transpolydatin: 400 mg + 40 mg (1 tablet a day for 10 days from the 24th day of cycle)
Number of subjects: 220
Study 26233289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet a day for 10 days from the 24th day of cycle)
Number of subjects: 220
Study 23758736 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MSCs (2 million cells/kg)
Number of subjects: 20
Study 23758736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PlasmaLyte A)
Number of subjects: 20
Study 20053471 — intervention group
Group type: EXPERIMENTAL
Intervention: FCE group
Number of subjects: 41
Study 20053471 — intervention group
Group type: COMPARATOR
Intervention: RCE group
Number of subjects: 41
Study 20053471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 18719439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 and 0.6 ng/ml)
Number of subjects: 37
Study 18719439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (up to 0.6 ng/ml)
Number of subjects: 37
Study 15772567 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplements (Novasoy, 60 mg total isoflavone equivalents/day)
Number of subjects: 50
Study 15772567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11828224 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 15
Study 11828224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15
Study 11828224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional advice
Number of subjects: 15
Study 11828224 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 15
Study 10980842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IIb/IIIa blockade
Number of subjects: 18000
Study 8773291 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 51
Study 8773291 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 51
Study 2344923 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with lactose as the sole carbohydrate (n = 7)
Number of subjects: 15
Study 2344923 — intervention group
Group type: COMPARATOR
Intervention: Formula with 50% of the carbohydrate as glucose polymer (n = 8)
Number of subjects: 15
Study 2344923 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the lactose intake
Number of subjects: 15
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormones and hormones and thiazide
Number of subjects: 315
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide alone
Number of subjects: 315
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 315
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 315
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride and D3
Number of subjects: 315
Study 6253303 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha D3
Number of subjects: 315
Study 6253303 — intervention group
Group type: COMPARATOR
Intervention: Combined placebo groups
Number of subjects: 315
Study 30183583 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE therapy
Number of subjects: 59
Study 26956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus energy restriction (n = 30)
Number of subjects: 60
Study 26956987 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction alone (n = 30)
Number of subjects: 60
Study 26301344 — intervention group
Group type: COMPARATOR
Intervention: Standard HF therapy
Number of subjects: 70
Study 26301344 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 70
Study 26301344 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 70
Study 26301344 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 70
Study 26301344 — intervention group
Group type: COMPARATOR
Intervention: Overall HF therapy
Number of subjects: 70
Study 23653910 — intervention group
Group type: COMPARATOR
Intervention: Paediatric fixed-dose combination granule for reconstitution (lamivudine/zidovudine/nevirapine 30/60/50 mg per 5 ml)
Number of subjects: 24
Study 23653910 — intervention group
Group type: COMPARATOR
Intervention: Single entities of the referenced products (lamivudine, zidovudine, nevirapine)
Number of subjects: 24
Study 19853922 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver psychoeducation for Stage I patients
Number of subjects: 113
Study 18086929 — intervention group
Group type: EXPERIMENTAL
Intervention: 162 mg aspirin
Number of subjects: 48422
Study 18086929 — intervention group
Group type: COMPARATOR
Intervention: 325 mg aspirin
Number of subjects: 48422
Study 15926000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoplastic meningitis-related encephalopathy cohort (20 patients)
Number of subjects: 40
Study 15926000 — intervention group
Group type: COMPARATOR
Intervention: No neoplastic meningitis-related encephalopathy cohort (20 patients)
Number of subjects: 40
Study 14679320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy with methylene blue
Number of subjects: 0
Study 14679320 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy
Number of subjects: 0
Study 14679320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 0
Study 11008919 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 396
Study 11008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I strains of H. pylori
Number of subjects: 396
Study 11008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate strains of H. pylori
Number of subjects: 396
Study 11008919 — intervention group
Group type: EXPERIMENTAL
Intervention: Type H strains of H. pylori
Number of subjects: 396
Study 11008919 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA protein antibodies
Number of subjects: 396
Study 9504817 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein expression profiles in ductal carcinoma specimens
Number of subjects: 0
Study 9504817 — intervention group
Group type: COMPARATOR
Intervention: Protein expression profiles in normal breast tissue
Number of subjects: 0
Study 8341859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol/Ipratropium Bromide (F/IB; 0.1 mg/0.04 mg)
Number of subjects: 24
Study 8341859 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (S; 0.2 mg)
Number of subjects: 24
Study 8341859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study 3786603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GABA administration
Number of subjects: 7
Study 3786603 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 7
Study 30187306 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback with Ritalin
Number of subjects: 14
Study 30187306 — intervention group
Group type: COMPARATOR
Intervention: Neurofeedback without Ritalin
Number of subjects: 14